Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic grass and/or birch allergen immunotherapy for allergic rhinoconjunctivitis
2013-004726-28Phase 2Terminated
- Sponsor
- Allergy Centre
- Start
- Nov 2013
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of birch pollen extract and ALK Alutard 5-grasses in allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Allergy Centre. Primary endpoint: Rhinoconjunctivitis Total Symptom Score and medication score over pollen seasons. Started Nov 2013; status: terminated.
02
Drugs
birch pollen extractALK Alutard 5-grasses
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2013-004726-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004726-28.